KR101799113B1 - 올리고머를 함유하는 치환된 방향족 트리아진 화합물 - Google Patents
올리고머를 함유하는 치환된 방향족 트리아진 화합물 Download PDFInfo
- Publication number
- KR101799113B1 KR101799113B1 KR1020117026044A KR20117026044A KR101799113B1 KR 101799113 B1 KR101799113 B1 KR 101799113B1 KR 1020117026044 A KR1020117026044 A KR 1020117026044A KR 20117026044 A KR20117026044 A KR 20117026044A KR 101799113 B1 KR101799113 B1 KR 101799113B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- oligomer
- alkyl
- substituted aromatic
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17793109P | 2009-05-13 | 2009-05-13 | |
US61/177,931 | 2009-05-13 | ||
PCT/US2010/034770 WO2010132691A1 (en) | 2009-05-13 | 2010-05-13 | Oligomer-containing substituted aromatic triazine compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120015311A KR20120015311A (ko) | 2012-02-21 |
KR101799113B1 true KR101799113B1 (ko) | 2017-11-17 |
Family
ID=42557491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117026044A Active KR101799113B1 (ko) | 2009-05-13 | 2010-05-13 | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 |
Country Status (10)
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101799113B1 (ko) | 2009-05-13 | 2017-11-17 | 넥타르 테라퓨틱스 | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 |
US10189859B2 (en) | 2013-12-21 | 2019-01-29 | Nektar Therapeutics | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine |
HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043772A2 (en) * | 2000-11-30 | 2002-06-06 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
WO2006027711A2 (en) * | 2004-08-26 | 2006-03-16 | Nicholas Piramal India Limited | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
WO2006047372A2 (en) * | 2004-10-25 | 2006-05-04 | Seradyn, Inc. | Lamotrigine analogs |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1147087B (it) | 1979-06-01 | 1986-11-19 | Wellcome Found | Nuovi preparati farmaceutici per il trattamento dei disordini del sistema nervoso centrale e procedimento per la loro preparazione |
US4810646A (en) | 1984-11-28 | 1989-03-07 | Massachusetts Institute Of Technology | Glucan compositions and process for preparation thereof |
US5028703A (en) | 1988-03-11 | 1991-07-02 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US4992540A (en) | 1984-11-28 | 1991-02-12 | Massachusetts Institute Of Technology | Glucan composition and process for preparation thereof |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
NZ594834A (en) * | 2003-12-16 | 2013-03-28 | Nektar Therapeutics | Method of preparing PEGylated protein molecules |
FR2869907B1 (fr) | 2004-05-05 | 2009-02-13 | Fabre Pierre Dermo Cosmetique | Derives dimeriques de 5,6-diphenyl-1,2,4-triazine et leurs utilisations |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
US7678551B2 (en) | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
WO2007109564A2 (en) | 2006-03-17 | 2007-09-27 | University Of Massachusetts | Yeast cell particles as oral delivery vehicles for antigens |
KR101799113B1 (ko) * | 2009-05-13 | 2017-11-17 | 넥타르 테라퓨틱스 | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 |
-
2010
- 2010-05-13 KR KR1020117026044A patent/KR101799113B1/ko active Active
- 2010-05-13 WO PCT/US2010/034770 patent/WO2010132691A1/en active Application Filing
- 2010-05-13 CN CN201080020581.5A patent/CN102421763B/zh active Active
- 2010-05-13 JP JP2012511017A patent/JP5656980B2/ja active Active
- 2010-05-13 AU AU2010248943A patent/AU2010248943B2/en active Active
- 2010-05-13 EP EP10721887.7A patent/EP2430003B1/en active Active
- 2010-05-13 US US13/319,824 patent/US8772479B2/en active Active
- 2010-05-13 CA CA2760219A patent/CA2760219C/en active Active
- 2010-05-13 MX MX2011012044A patent/MX2011012044A/es active IP Right Grant
-
2011
- 2011-11-10 IL IL216314A patent/IL216314B/en active IP Right Grant
-
2014
- 2014-05-20 US US14/282,732 patent/US8895553B2/en active Active
- 2014-10-30 US US14/528,444 patent/US9266845B2/en active Active
-
2016
- 2016-01-15 US US14/996,801 patent/US9617228B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002043772A2 (en) * | 2000-11-30 | 2002-06-06 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
WO2006027711A2 (en) * | 2004-08-26 | 2006-03-16 | Nicholas Piramal India Limited | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
WO2006047372A2 (en) * | 2004-10-25 | 2006-05-04 | Seradyn, Inc. | Lamotrigine analogs |
Non-Patent Citations (1)
Title |
---|
Justyna Ławecka 외 3명. Tetrahedron Letters. Vol. 49, 2008년, pp. 723-726* |
Also Published As
Publication number | Publication date |
---|---|
AU2010248943B2 (en) | 2015-05-21 |
KR20120015311A (ko) | 2012-02-21 |
JP5656980B2 (ja) | 2015-01-21 |
US20140256732A1 (en) | 2014-09-11 |
US20120122871A1 (en) | 2012-05-17 |
US9617228B2 (en) | 2017-04-11 |
MX2011012044A (es) | 2011-12-14 |
IL216314B (en) | 2018-05-31 |
CN102421763B (zh) | 2015-06-17 |
AU2010248943A1 (en) | 2011-11-10 |
JP2012526847A (ja) | 2012-11-01 |
IL216314A0 (en) | 2012-01-31 |
US20150065706A1 (en) | 2015-03-05 |
EP2430003B1 (en) | 2019-02-27 |
US8772479B2 (en) | 2014-07-08 |
CA2760219A1 (en) | 2010-11-18 |
US9266845B2 (en) | 2016-02-23 |
US20160194294A1 (en) | 2016-07-07 |
CN102421763A (zh) | 2012-04-18 |
WO2010132691A1 (en) | 2010-11-18 |
US8895553B2 (en) | 2014-11-25 |
CA2760219C (en) | 2016-08-16 |
EP2430003A1 (en) | 2012-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101561707B1 (ko) | 올리고머―항히스타민제 컨주게이트 | |
US10265411B2 (en) | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | |
US9399033B2 (en) | Oligomer-containing pyrrolidine compounds | |
KR101799113B1 (ko) | 올리고머를 함유하는 치환된 방향족 트리아진 화합물 | |
WO2009054916A2 (en) | Oligomer conjugates of lidocaine and its derivatives | |
JP6265998B2 (ja) | オリゴマー含有ベンズアミド系化合物 | |
US9540330B2 (en) | Oligomer-containing hydantoin compounds | |
EP2400989B1 (en) | Gabapentin-peg conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20111101 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
AMND | Amendment | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20150508 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20160912 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20170706 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20160912 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20170706 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20170313 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20150508 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20170904 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20170803 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20170706 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20170313 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20150508 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20171113 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20171113 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20210929 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20230921 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20240925 Start annual number: 8 End annual number: 8 |